Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by Vestcor Inc

Vestcor Inc increased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 21.9% during the 4th quarter, Holdings Channel.com reports. The fund owned 15,589 shares of the life sciences company’s stock after purchasing an additional 2,796 shares during the quarter. Vestcor Inc’s holdings in Illumina were worth $2,083,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ILMN. Golden State Wealth Management LLC purchased a new position in shares of Illumina during the fourth quarter worth about $32,000. Versant Capital Management Inc boosted its position in shares of Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares during the period. Bank Julius Baer & Co. Ltd Zurich purchased a new position in Illumina during the 4th quarter worth approximately $45,000. Assetmark Inc. increased its position in Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after buying an additional 296 shares during the period. Finally, TD Private Client Wealth LLC lifted its stake in Illumina by 58.5% in the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after buying an additional 141 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on ILMN shares. Robert W. Baird cut their target price on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a report on Wednesday, March 5th. Guggenheim dropped their price objective on shares of Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Citigroup decreased their target price on shares of Illumina from $130.00 to $90.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Stephens restated an “overweight” rating and issued a $156.00 price target on shares of Illumina in a research report on Tuesday. Finally, HSBC downgraded Illumina from a “buy” rating to a “hold” rating and set a $100.00 price objective for the company. in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Illumina has an average rating of “Moderate Buy” and a consensus price target of $140.90.

Illumina Stock Up 1.8 %

ILMN stock opened at $85.60 on Friday. Illumina, Inc. has a 52 week low of $80.18 and a 52 week high of $156.66. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The company has a market cap of $13.56 billion, a P/E ratio of -11.15, a P/E/G ratio of 1.60 and a beta of 1.17. The company’s 50-day moving average price is $113.52 and its 200 day moving average price is $129.88.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.